BWAY Stock Overview Develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
BrainsWay Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for BrainsWay Historical stock prices Current Share Price ₪16.80 52 Week High ₪20.56 52 Week Low ₪9.35 Beta 0.40 1 Month Change -7.23% 3 Month Change 9.88% 1 Year Change 34.72% 3 Year Change 37.93% 5 Year Change -1.52% Change since IPO 8.92%
Recent News & Updates
BrainsWay Ltd. Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder Dec 13
BrainsWay Ltd. Reports Promising Feasibility Data Showing Pain Reduction with Deep Tms Therapy Nov 21
New minor risk - Shareholder dilution Nov 16
Third quarter 2024 earnings released: EPS: US$0.02 (vs US$0.01 loss in 3Q 2023) Nov 14
BrainsWay Ltd. Raises Earnings Guidance for the Full Year 2024 Nov 13
BrainsWay Ltd. to Report Q3, 2024 Results on Nov 12, 2024 Oct 31 See more updates
BrainsWay Ltd. Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder Dec 13
BrainsWay Ltd. Reports Promising Feasibility Data Showing Pain Reduction with Deep Tms Therapy Nov 21
New minor risk - Shareholder dilution Nov 16
Third quarter 2024 earnings released: EPS: US$0.02 (vs US$0.01 loss in 3Q 2023) Nov 14
BrainsWay Ltd. Raises Earnings Guidance for the Full Year 2024 Nov 13
BrainsWay Ltd. to Report Q3, 2024 Results on Nov 12, 2024 Oct 31
BrainsWay Ltd. to Report Q3, 2024 Results on Nov 22, 2024 Oct 29 BrainsWay Ltd. announced that it has received $20.006615 million in funding from Valor Management LLC Oct 16
Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Sep 10
BrainsWay Ltd. Appoints Richard A. Bermudes, M.D. as Chief Medical Officer, Effective September 1, 2024 Aug 29
After Leaping 27% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar Aug 23
New major risk - Share price stability Aug 07
Second quarter 2024 earnings released: EPS: US$0.02 (vs US$0.05 loss in 2Q 2023) Aug 07 BrainsWay Ltd. Updates Revenue Guidance for the Full Year of 2024 Aug 07
BrainsWay Ltd. to Report Q2, 2024 Results on Aug 06, 2024 Jul 23
BrainsWay Ltd. Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS for Depression for the Month of June 2024 Jun 13
BrainsWay Ltd. Receives Expanded FDA Labeling to Treat Late Life Depression Jun 05
BrainsWay Ltd., Annual General Meeting, Jun 17, 2024 May 14
First quarter 2024 earnings released: EPS: US$0.003 (vs US$0.07 loss in 1Q 2023) May 09
BrainsWay Ltd. Reiterates Revenue Guidance for the Year 2024 May 09
We Think BrainsWay (TLV:BWAY) Can Easily Afford To Drive Business Growth May 03
BrainsWay Ltd. to Report Q1, 2024 Results on May 08, 2024 Apr 26
BrainsWay Ltd. Announces Publish Review Results Highlighting Potential of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a Novel Therapeutic Approach for Parkinson's Disease Apr 05
Brainsway Announces Positive Results in Late-Life Depression Post-Marketing Analysis Mar 29
Full year 2023 earnings released: US$0.13 loss per share (vs US$0.41 loss in FY 2022) Mar 07
New major risk - Revenue and earnings growth Mar 07
Brainsway Ltd. Provides Earnings Guidance for Full Year 2024 Mar 06
BrainsWay Ltd. to Report Q4, 2023 Results on Mar 06, 2024 Feb 22
New minor risk - Market cap size Jan 24
BrainsWay Ltd. Announces New Rotational Field Technology in Two New Feasibility Studies Jan 10
BrainsWay Ltd.'s (TLV:BWAY) P/S Is Still On The Mark Following 26% Share Price Bounce Dec 25
We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely Dec 21
Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.15 loss in 3Q 2022) Nov 16
BrainsWay Ltd. Announces Publishes the First Coverage Recommendations for Smoking Addiction Treatment Using TMS Nov 04
BrainsWay Ltd. to Report Q3, 2023 Results on Nov 15, 2023 Nov 02
BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) for Depression Oct 17
We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely Sep 19
Forecast to breakeven in 2025 Aug 10
BrainsWay Ltd. to Report Q2, 2023 Results on Aug 09, 2023 Jul 28
We're Keeping An Eye On BrainsWay's (TLV:BWAY) Cash Burn Rate Jun 01
Brainsway Ltd. Announces CFO Changes May 24
No longer forecast to breakeven May 18
BrainsWay Ltd. to Report Q1, 2023 Results on May 17, 2023 May 04 Mar 16
Full year 2022 earnings released: US$0.40 loss per share (vs US$0.21 loss in FY 2021) Mar 16 BrainsWay Ltd., Annual General Meeting, Mar 20, 2023
BrainsWay Ltd. Appoints Ami Boehm as an Independent Director Jan 13
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™ Jan 12
Neuronetics Settles Litigation Against BrainsWay Ltd. and BrainsWay USA Inc Jan 11
Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.05 loss in 3Q 2021) Nov 18
No longer forecast to breakeven Nov 16
BrainsWay Ltd. to Report Q3, 2022 Results on Nov 16, 2022 Nov 03
BrainsWay Ltd Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS Sep 15
BrainsWay Ltd. Receives New FDA Clearance for Treating Depression and Anxious Depression Aug 30
We Think BrainsWay (TLV:BWAY) Can Afford To Drive Business Growth Aug 15
Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.06 loss in 2Q 2021) Aug 12
No longer forecast to breakeven Aug 10
BrainsWay Ltd. to Report Q2, 2022 Results on Aug 10, 2022 Jul 28
BrainsWay Ltd. Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression Jun 29
Brainsway Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™ Jun 22
BrainsWay Ltd. Promotes Hadar Levy to Senior Vice President and Chief Operating Officer May 13
BrainsWay (TLV:BWAY) Is In A Good Position To Deliver On Growth Plans May 13
First quarter 2022 earnings released: US$0.06 loss per share (vs US$0.11 loss in 1Q 2021) May 12
Neuronetics, Inc. Files Federal Lawsuit Against BrainsWay Ltd. for Misleading Psychiatrists and Patients May 12
BrainsWay Ltd. to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society May 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 10
BrainsWay Ltd. to Report Q4, 2021 Results on Mar 09, 2022 Mar 01
BrainsWay (TLV:BWAY) Is In A Strong Position To Grow Its Business Jan 31
BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System Jan 13
Forecast to breakeven in 2024 Jan 01
Brainsway Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects Dec 10
Third quarter 2021 earnings released: US$0.05 loss per share (vs US$0.04 loss in 3Q 2020) Nov 18
Forecast to breakeven in 2023 Nov 18
FDA Clears BrainsWay Deep TMS System for Decreasing Anxiety Symptoms in Depressed Patients Aug 19
Second quarter 2021 earnings released: EPS US$0.06 (vs US$0.03 loss in 2Q 2020) Aug 12
BrainsWay Announces Positive OCD Coverage Policy by Blue Cross Blue Shield Licensee HCSC Jun 03
BrainsWay Announces First Draft Proposal for Obsessive-Compulsive Disorder Coverage Jun 02
BrainsWay Ltd. Announces First of Its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™ May 25
First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in 1Q 2020) May 22
Brainsway Ltd. Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder Apr 27
Full year 2020 earnings released: US$0.24 loss per share (vs US$0.50 loss in FY 2019) Apr 21
Full year 2020 earnings released: US$0.24 loss per share (vs US$0.50 loss in FY 2019) Mar 26
Brainsway Ltd. to Report Q4, 2020 Results on Mar 24, 2021 Mar 12
What Is The Ownership Structure Like For Brainsway Ltd. (TLV:BWAY)? Mar 02
Brainsway Ltd. has completed a Follow-on Equity Offering in the amount of $39.287 million. Feb 25
Third quarter 2020 earnings released: US$0.04 loss per share (vs US$0.12 loss in 3Q 2019) Feb 24
Revenue beats expectations Feb 24
New 90-day high: ₪15.53 Feb 18 Brainsway Ltd., Annual General Meeting, Mar 04, 2021
What Type Of Returns Would Brainsway's(TLV:BWAY) Shareholders Have Earned If They Purchased Their SharesFive Years Ago? Jan 25
New 90-day high: ₪14.00 Jan 21
New 90-day high: ₪11.40 Dec 31
Brainsway Ltd. (TLV:BWAY): Is Breakeven Near? Dec 26
Third quarter 2020 earnings released: US$0.04 loss per share Nov 20 Shareholder Returns BWAY IL Medical Equipment IL Market 7D -1.1% 0.1% 0.5% 1Y 34.7% 18.0% 23.7%
See full shareholder returns
Return vs Market: BWAY exceeded the IL Market which returned 23% over the past year.
Price Volatility Is BWAY's price volatile compared to industry and market? BWAY volatility BWAY Average Weekly Movement 5.9% Medical Equipment Industry Average Movement 7.3% Market Average Movement 4.2% 10% most volatile stocks in IL Market 8.0% 10% least volatile stocks in IL Market 3.0%
Stable Share Price: BWAY's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: BWAY's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry.
Show more BrainsWay Ltd. Fundamentals Summary How do BrainsWay's earnings and revenue compare to its market cap? BWAY fundamental statistics Market cap ₪631.55m Earnings (TTM ) ₪5.46m Revenue (TTM ) ₪140.61m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BWAY income statement (TTM ) Revenue US$38.63m Cost of Revenue US$9.82m Gross Profit US$28.81m Other Expenses US$27.31m Earnings US$1.50m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 05:46 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BrainsWay Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kyle Mikson Cantor Fitzgerald & Co. Raghuram Selvaraju H.C. Wainwright & Co. Jeffrey Cohen Ladenburg Thalmann & Company
Show 4 more analysts 
